Treatment Advances Position Lilly as Weight-Loss Heavyweight

For every patient Eli Lilly helped downsize with its obesity drug Zepbound, rival Novo Nordisk’s purse got a little lighter, too. After Novo reported disappointing results Tuesday, all eyes are on Eli’s earnings today, evaluating whether the firm has what it takes to, once and for all, take the Danish firm’s krone. SUBSCRIBE:  Receive more of our free The Daily Upside newsletter. READ ALSO: Molasses-Like Jobs Growth Not Enough to Trump Fed’s Rate-Cut Inertia and Bitcoin Sinks to 14-Month Low amid Plot Tw ...